Search

Displaying results 3031 - 3040 of 7687 in total
  1. Drug

    Clemastine

    go.drugbank.com/drugs/DB00283
    ApprovedInvestigational

    An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.

    Mixtures: Tavist-D Tablets
  2. Drug

    Saw palmetto

    go.drugbank.com/drugs/DB14360
    Approved

    It is not an approved drug.

  3. Drug

    Methoxamine

    go.drugbank.com/drugs/DB00723
    ApprovedInvestigationalWithdrawn

    An alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system.

  4. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to

  5. Drug

    Psilocybin

    go.drugbank.com/drugs/DB11664
    Investigational

    In November, 2019, it was granted Breakthrough Therapy status by the FDA.

  6. Drug

    Aldoxorubicin

    go.drugbank.com/drugs/DB06013
    Investigational

    Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.

  7. Drug

    N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine

    go.drugbank.com/drugs/DB14196
    Approved

    N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine is a component of black rubber. It is also a dermatological sensitizer and allergen. Sensitivity to N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine may be identified with a clinical patch test.

  8. Drug

    Didesmethylrocaglamide

    go.drugbank.com/drugs/DB15496
    Experimental

    Didesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their inse...

  9. Drug

    Sofpironium

    go.drugbank.com/drugs/DB19325
    Approved

    [L51108,L51109] Sofpironium bromide (Sofdra) was approved by the FDA in June 2024 for the topical treatment of primary axillary hyperhidrosis.

  10. Drug

    REC-994

    go.drugbank.com/drugs/DB15616
    Investigational

    REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).